Inhibikase Therapeutics Inc

NASDAQ:IKT   12:41:43 AM EDT
0.61
+0.01 (+2.11%)
Earnings Announcements

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results, Highlights Recent Period Activity

Published: 11/14/2022 22:53 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity.
Inhibikase Therapeutics Inc - Net Loss for Three Months Ended September 30, 2022 Was $4.49 Million, Or $0.18 per Share.
Inhibikase Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities Were $26.5 Million As of September 30, 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.